...And Grappling With Its Risks

Averting Catastrophe: Strategies for Regulating Risky Technologies. Joseph G. Morone and Edward J. Woodhouse. University of California Press, Berkeley, 1986. 215 pp. $17.95 The year 1986, which began as we were still reeling from Bhopal, brought Chernobyl's reminder of the international potential of major technological accidents, Challenger's reminder of the fallibility of even the most sophisticated engineering management systems (and human hubris), Lake Nyos' reminder that nature itself is not

Written byWilliam Lowrance
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Thus we hardly could be more sensitized to the question Morone and Woodhouse raise in their book: "Why, despite close calls, have risky civilian technologies produced no catastrophes in the United States? Have we simply been lucky—or is our good fortune at least partly the result of deliberate efforts to protect against these hazards?"

The authors are social process-oriented. They confess: "At the outset of this research, we approached this subject with the commonly held assumption that the United States had botched the job of regulating risky technologies. Yet when we actually delved into how regulators have coped with the various risks, we discovered a surprisingly intelligent process."

Five case studies on U.S. civilian technologies form the core of the analysis in Averting Catastrophe: toxic chemicals, nuclear reactors, recombinant DNA research, threats to the ozone layer and the atmospheric greenhouse problem. As the authors recognize, any book based on only ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies